Author + information
- Received September 28, 2015
- Revision received November 17, 2015
- Accepted December 14, 2015
- Published online March 1, 2016.
- Wissam A. Jaber, MDa,
- Pete P. Fong, MDb,
- Giora Weisz, MDc,
- Omar Lattouf, MDd,
- James Jenkins, MDe,
- Kenneth Rosenfield, MD, MHCDSf,
- Tanveer Rab, MDa,∗ ( and )
- Stephen Ramee, MDg
- aDivision of Cardiology, Emory University School of Medicine, Atlanta, Georgia
- bVanderbilt Heart and Vascular Institute, Nashville, Tennessee
- cDivision of Cardiology, Shari Zadek Medical Center, Jerusalem, Israel
- dDivision of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia
- eOchsner Medical Center, New Orleans, Louisiana
- fSection of Vascular Medicine, & Intervention, Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts
- gStructural and Valvular Heart Disease Program, Ochsner Medical Center, New Orleans, Louisiana
- ↵∗Reprint requests and correspondence:
Dr. Tanveer Rab, Division of Cardiology, Emory University Hospital, 1364 Clifton Road Northeast, F-606, Atlanta, Georgia 30322.
Compared with recent advances in treatment of serious cardiovascular diseases, such as myocardial infarction and stroke, the treatment and outcome of acute pulmonary embolism (PE) have remained relatively unchanged over the last few decades. This has prompted several experts to call for the formation of multidisciplinary PE response teams with a more proactive approach to the treatment of PE. In the current document, we discuss the formation of such teams and describe the available treatment options beyond anticoagulation, with a focus on the interventional approach. Acknowledging the paucity of data to support widespread adoption of such techniques, we call for the collection of outcomes data in multicenter registries and support for randomized trials to evaluate interventional treatments in patients with high-risk PE.
The views expressed in this manuscript by the American College of Cardiology (ACC's) Interventional Council do not necessarily reflect the views of the Journal of the American College of Cardiology or the ACC.
Dr. Rosenfield has served as a consultant to Abbott, Cardinal Health, Inari Medical, Surmodics, Volcano, Capture Vascular, and Shockwave; has served as a board member for VIVA Physicians, a 501c3 organization; has received research support from the National Institutes of Health, Atrium, Lutonix-Bard, Abbott Vascular, and Gore; and has personal equity in CardioMems, Embolitech, MD Insider, Primacea, and Vortex. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received September 28, 2015.
- Revision received November 17, 2015.
- Accepted December 14, 2015.
- American College of Cardiology Foundation